Clinical Research Directory
Browse clinical research sites, groups, and studies.
Haematococcus Pluvialis Astaxanthin for Brain Aging
Sponsor: Capital Medical University
Summary
We recruit community-dwelling older adults aged 50 and above for a 6-month intervention. Participants are divided into three groups: Placebo Group, Low-Dose Group ( 6 mg/d Haematococcus pluvialis Astaxanthin), High-Dose Group (12 mg/d Haematococcus pluvialis Astaxanthin). Peripheral blood samples and Other tests are collected at baseline, 3 months, and 6 months to measure mitochondrial function and oxidative stress levels. Assessments include: 1.Cognitive \& Neurophysiological Assessment: Using the MoCA (Montreal Cognitive Assessmentscale) and ERP (specifically P300) monitoring. 2.Brain Imaging: MRI (Magnetic resonance imaging) is used to analyze changes in brain function. 3.Metabolomics: A series of laboratory techniques are used to analyze routine metabolic indices, plasma astaxanthin, mitochondrial function, oxidative stress markers, and cognition-related neurobiomarkers.
Official title: Effects and Mechanism of Haematococcus Pluvialis Astaxanthin on Inhibiting Brain Aging Through Improving Mitochondrial Function
Key Details
Gender
All
Age Range
50 Years - Any
Study Type
INTERVENTIONAL
Enrollment
120
Start Date
2026-05-01
Completion Date
2027-02-01
Last Updated
2026-01-30
Healthy Volunteers
Yes
Conditions
Interventions
Low-Dose AST
Low-Dose AST Group:6 mg/d Astaxanthin (Haematococcus pluvialis)
High-Dose AST
High-Dose Group: 12 mg/d Astaxanthin (Haematococcus pluvialis)
Placebo
Placebo